In 551 virologically suppressed adults with HIV-1, switching to doravirine/islatravir was non-inferior to continuing baseline oral ART at week 48 (viral load ≥50 copies/mL 1.4% vs 4.9%); treatment-related adverse events were commoner (12.0% vs 4.9%).
RCTn = 553
Orkin et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial